tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Knoop C et al. FK 506 rescue therapy for irreversible airway rejection in heart-lung transplant recipients: report on five cases. 1994 Transplant. Proc. pmid:7527957
Candinas D et al. Efficacy of leflunomide in combination with current immunosuppressive agents in rat cardiac allotransplantation. 1994 Transplant. Proc. pmid:7527959
Yuan QS et al. Rescue therapy with tacrolimus in renal graft patients with cyclosporine A-induced hepatotoxicity: a preliminary study. 2000 Transplant. Proc. pmid:11119896
Morphological characteristics of renal allografts showing renal dysfunction under FK 506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK 506 nephropathy? Japanese FK 506 Study Group. 1993 Transplant. Proc. pmid:7679824
Kato H et al. Spontaneous proliferation of peripheral blood mononuclear cells as an indicator for insufficient plasma levels of FK 506 in the early phase after liver transplantation. 1994 Transplant. Proc. pmid:7513481
Nishikawa K et al. Experimental studies of vascularized joint allografts in rats. 1994 Transplant. Proc. pmid:7513482
Morris RE In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. 1991 Transplant. Proc. pmid:1721257
Loss M et al. Glucose and lipid metabolism in liver transplant patients under long-term tacrolimus (FK 506) monotherapy. 1996 Transplant. Proc. pmid:8623210
Van Thiel DH et al. Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. 1990 Transplant. Proc. pmid:1689893
Shoji T et al. Long-term acceptance of porcine pulmonary allografts without chronic rejection. 2005 Jan-Feb Transplant. Proc. pmid:15808551
Asensio M et al. Experience with tacrolimus as primary immunosuppressor in pediatric liver transplant. 2002 Transplant. Proc. pmid:11959208
Yao B et al. The incidence of posttransplantation diabetes mellitus during follow-up in kidney transplant recipients and relationship to Fok1 vitamin D receptor polymorphism. 2013 Jan-Feb Transplant. Proc. pmid:23375298
Millis JM et al. Successful use of tacrolimus for initial rejection episodes after liver transplantation. 1998 Transplant. Proc. pmid:9636569
Harihara Y et al. Correlation between graft size and necessary tacrolimus dose after living-related liver transplantation. 2000 Transplant. Proc. pmid:11120116
Fukuzaki T et al. Induction of unresponsiveness to islet allograft by preoperative donor spleen cell injection and FK 506 treatment. 1993 Transplant. Proc. pmid:7680173
Oishi M et al. A case of hyperkalemic distal renal tubular acidosis secondary to tacrolimus in living donor liver transplantation. 2000 Transplant. Proc. pmid:11120143
van Hooff JP et al. Tacrolimus and glucose metabolism. 1999 Transplant. Proc. pmid:10576044
Nakamuta M et al. Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells. 2005 Transplant. Proc. pmid:16387179
Kim HC et al. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center. 2004 Transplant. Proc. pmid:15518753
Loréal O et al. FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. 1991 Transplant. Proc. pmid:1721289
Matsuzaki T et al. Liver transplantation for diethylnitrosamine-induced hepatocellular carcinoma in rats. 1992 Transplant. Proc. pmid:1373547
Soriano S et al. Single-center experience with initial intravenous dosing of tacrolimus after kidney transplantation. 1999 Transplant. Proc. pmid:10576045
McCauley J et al. Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. 1991 Transplant. Proc. pmid:1721290
Pirenne J et al. Bone marrow augmentation of kidney allografts can cause graft-versus-host disease in immunosuppressed recipients. 1996 Transplant. Proc. pmid:8623472
Ciancio G et al. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy. 1996 Transplant. Proc. pmid:8623473
Thomas FT et al. Comparative efficacy of immunosuppressive drugs in xenografting. 1990 Transplant. Proc. pmid:1693452
Comuzzi C et al. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients. 2010 Transplant. Proc. pmid:20534291
Gruessner RW Antibody induction therapy in pancreas transplantation. 1998 Transplant. Proc. pmid:9636632
Marchewka Z et al. Kidney graft function in long-term cyclosporine and tacrolimus treatment: comparative study with nephrotoxicity markers. 2009 Transplant. Proc. pmid:19545703
Lentine KL et al. Variation in Comedication Use According to Kidney Transplant Immunosuppressive Regimens: Application of Integrated Registry and Pharmacy Claims Data. Transplant. Proc. pmid:26915843
Herrero MJ et al. Clinical interest of pharmacogenetic polymorphisms in the immunosuppressive treatment after heart transplantation. 2010 Transplant. Proc. pmid:20970643
Zhao DQ et al. Sirolimus-Based Immunosuppressive Regimens in Renal Transplantation: A Systemic Review. Transplant. Proc. pmid:26915834
Platz KP et al. Indications for mycofenolate mofetil therapy after liver transplantation. 1997 Transplant. Proc. pmid:9365601
Lischke R et al. Initial single-center experience with sirolimus after lung transplantation. 2006 Transplant. Proc. pmid:17112886
Curro G et al. Transient ischemic attack after rizatriptan administration in a liver transplant recipient: a case report. 2006 Transplant. Proc. pmid:17112920
Reyes J et al. Lymphoproliferative disease after intestinal transplantation under primary FK 506 immunosuppression. 1994 Transplant. Proc. pmid:7518137
Falkiewicz K et al. Tacrolimus decreases tubular phosphate wasting in renal allograft recipients. 2003 Transplant. Proc. pmid:14529892
Meiser BM et al. Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. 1993 Transplant. Proc. pmid:7682363
O'Rourke M et al. Recovery of delayed-type hypersensitivity following liver transplantation. 1995 Transplant. Proc. pmid:7533369
Fukuzawa M et al. Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. 1991 Transplant. Proc. pmid:1721321
Stockmann M et al. Influence of immunosuppressive drugs on intestinal epithelial transport function. 2002 Transplant. Proc. pmid:12176434
Waller JR et al. Effect of rapamycin in combination with calcineurin inhibitors, FK506 and cyclosporin, following arterial injury. 2002 Transplant. Proc. pmid:12176449
Hayes D et al. Aerosolized tacrolimus: a case report in a lung transplant recipient. 2010 Transplant. Proc. pmid:21094875
Numakura K et al. Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients. 2005 Transplant. Proc. pmid:15919487
Izutani H et al. Graft coronary arteriosclerosis in rat heart transplant model with FK 506 short-term administration. 1995 Transplant. Proc. pmid:7533425
Funayama Y et al. Changes in cell adhesion molecules after small bowel transplantation in rats. 1995 Transplant. Proc. pmid:7533426
Torre-Cisneros J et al. The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression. 1991 Transplant. Proc. pmid:1721353
Colak T et al. Effect of conversion from cyclosporine to tacrolimus on lipid profiles in renal transplant recipients. 2002 Transplant. Proc. pmid:12270321
Paul AA et al. CMV retinitis and the use of FK 506. 1991 Transplant. Proc. pmid:1721354
Waller JR et al. Primary immunosuppression with tacrolimus is associated with a reduction in renal allograft fibrosis compared with neoral therapy. 2002 Transplant. Proc. pmid:12176496
Prates LC et al. Pain syndrome induced by calcineurin inhibitor and resolved by conversion to sirolimus in a child after kidney transplantation: a case report. 2012 Transplant. Proc. pmid:23026634
Sasaki K et al. Effect of FK 506 and splenectomy on orthotopic small bowel xenotransplantation in the hamster-to-rat animal models. 1998 Transplant. Proc. pmid:9838521
Cheng CY et al. Intervention of Online Percent Coefficient of Variation Reporting System Reduces the Variability of Tacrolimus Trough Concentration in Kidney Transplant Recipients. 2018 Transplant. Proc. pmid:30316366
Marino IR et al. Preoperative assessment of risk in liver transplantation: a multivariate analysis in 2376 cases of the UW era. 1997 Feb-Mar Transplant. Proc. pmid:9123079
Alessiani M et al. Intestinal transplantation with and without the colon in FK 506 immunosuppressed pigs. 1996 Transplant. Proc. pmid:8908021
Nozaki S et al. Effect of brequinar sodium on accelerated cardiac allograft rejection in presensitized recipients. 1994 Transplant. Proc. pmid:7520633
Goller AL et al. Loss of serum bicarbonate after discordant liver xenotransplantation. 2000 Transplant. Proc. pmid:10936383
Endoh M et al. Nonmuscle myosin heavy chain and metalloproteinase-2 expression in concordant pulmonary xenografts. 2000 Transplant. Proc. pmid:10936397
Chen WY et al. Betel Nut Chewing Is Associated With Reduced Tacrolimus Concentration in Taiwanese Liver Transplant Recipients. 2017 Transplant. Proc. pmid:28219593
Morris RE et al. Immunopharmacology of FK-506. 1989 Transplant. Proc. pmid:2468201
Tauxe WN et al. A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. 1991 Transplant. Proc. pmid:1721386
Boots JM et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. 2002 Transplant. Proc. pmid:12176542
Citterio F et al. Steroid withdrawal from tacrolimus-based therapy in renal transplant patients. 2002 Transplant. Proc. pmid:12176545
Kato H et al. Long-Term Influence of CYP3A5 Gene Polymorphism on Pharmacokinetics of Tacrolimus and Patient Outcome After Living Donor Liver Transplantation. 2016 Transplant. Proc. pmid:27320564
Yang HC et al. Tacrolimus/"low-dose" mycophenolate mofetil versus microemulsion cyclosporine/"low-dose" mycophenolate mofetil after kidney transplantation--1-year follow-up of a prospective, randomized clinical trial. 1999 Feb-Mar Transplant. Proc. pmid:10083501
Hsu KH et al. Combined sirolimus-calcineurin inhibitor immunosuppressive therapy in simultaneous heart and kidney transplantation: a retrospective analysis of a single hospital's experience. 2010 Transplant. Proc. pmid:20430208
Steinmueller T et al. The effect of cyclosporine vs FK 506 on glucose metabolism. 1999 Feb-Mar Transplant. Proc. pmid:10083504
Mao PC et al. Trends in the use of immunosuppressive agents by outpatients after renal transplantation at a medical center in southern Taiwan. 2012 Transplant. Proc. pmid:22310611
Galvao FH et al. Experimental animal model of graft-versus-host disease (GVHD) after small-bowel transplantation: characteristics of the model and application to developing treatment strategies. 1997 Feb-Mar Transplant. Proc. pmid:9123488
Ayar Y et al. Risk Factors Affecting Graft and Patient Survivals After Transplantation From Deceased Donors in a Developing Country: A Single-Center Experience. 2017 Transplant. Proc. pmid:28219583
Tatekawa Y et al. Intragraft expression of p38 in rat small bowel transplantation. 2000 Transplant. Proc. pmid:10995948
Karamperis N et al. Comparison of the pharmacokinetics of tacrolimus and cyclosporine at equivalent molecular doses. 2003 Transplant. Proc. pmid:12826146
Tzakis AG et al. FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. 1991 Transplant. Proc. pmid:1721416
Watanabe K et al. Immunosuppressive effect of bactobolamine in rat liver allotransplantation. 1996 Transplant. Proc. pmid:8658697
Chang HR et al. Sirolimus addition is beneficial for renal allograft dysfunction due to simultaneous acute rejection episode and calcineurin inhibitor nephrotoxicity. 2004 Transplant. Proc. pmid:15621119
Land W et al. Tacrolimus versus cyclosporine in primary simultaneous pancreas-kidney transplantation: preliminary results at 1 year of a large multicenter trial. 2002 Transplant. Proc. pmid:12176625
Zamauskaite A et al. FK506 and CsA differ in their effect on intracellular cytokine expression following kidney transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267184
Donadio C et al. Tubular damage and impairment of renal function in transplanted kidneys. 1998 Transplant. Proc. pmid:9723381
Varghese Z et al. Oxidizability of low-density lipoproteins from Neoral and tacrolimus-treated renal transplant patients. 1998 Transplant. Proc. pmid:9723384
Gruttadauria S et al. A safe immunosuppressive protocol in adult-to-adult living related liver transplantation. 2006 Transplant. Proc. pmid:16757278
Duzova A et al. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. 2003 Transplant. Proc. pmid:14697926
Davies CB et al. Effects of donor-specific transfusion, cyclosporine A and FK 506 on rat cardiac allograft survival. 1991 Transplant. Proc. pmid:1721448
Reichenspurner H et al. First experience with FK 506 for treatment of chronic pulmonary rejection. 1995 Transplant. Proc. pmid:7540775
Abu-Elmagd K et al. FK 506: a new therapeutic agent for severe recalcitrant psoriasis. 1991 Transplant. Proc. pmid:1721449
Dé P et al. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3? 1993 Transplant. Proc. pmid:7689279
Ueda D et al. Influence of FK 506 on renal blood flow. 1993 Transplant. Proc. pmid:7689280
Aidong W et al. Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation. 2004 Transplant. Proc. pmid:15561258
Sigal NH et al. Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A. 1991 Transplant. Proc. pmid:1712132
Uber PA et al. Ethnic disparities in the pharmacologic characteristics of tacrolimus in heart transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267428
Isobe M et al. Downregulation of endothelin expression in allograft coronary arteries after gene therapy targeting Cdk2 kinase. 1998 Transplant. Proc. pmid:9636407
Ciancio G et al. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. 2010 Transplant. Proc. pmid:21094804
Tsujimura K et al. Effect of Influenza Vaccine in Patients With Kidney Transplant. 2018 Transplant. Proc. pmid:30316375
Malinowski K et al. Effect of different anti-rejection regimens on the expression of differentiation and activation markers on the surface of host lymphocytes. 2000 Transplant. Proc. pmid:10856579
McLaughlin GE et al. Effect of aminophylline on urine flow in children with tacrolimus-induced renal insufficiency. 2000 Transplant. Proc. pmid:10856596
Xie L et al. Pretransplantation Risk Factors Associated With New-onset Diabetes After Living-donor Kidney Transplantation. 2016 Transplant. Proc. pmid:27931572
Mohsin N et al. Pharmacokinetics of mycophenolate mofetil in Omani patients on cyclosporine or tacrolimus. 2015 Transplant. Proc. pmid:26036534
Jørgensen KA et al. Optimal time for determination of blood tacrolimus level. 2001 Nov-Dec Transplant. Proc. pmid:11750358
Ott R et al. Conversion from tacrolimus to Neoral in liver and kidney transplant recipients. 2001 Nov-Dec Transplant. Proc. pmid:11750359
Loss GE et al. Reversal of delayed hyperacute renal allograft rejection with a tacrolimus-based therapeutic regimen. 1998 Transplant. Proc. pmid:9636508
Kliem V et al. Tacrolimus for steroid- and OKT3-resistant rejection in kidney recipients. 1998 Transplant. Proc. pmid:9636509